JP2021513562A5 - - Google Patents
Info
- Publication number
- JP2021513562A5 JP2021513562A5 JP2020564814A JP2020564814A JP2021513562A5 JP 2021513562 A5 JP2021513562 A5 JP 2021513562A5 JP 2020564814 A JP2020564814 A JP 2020564814A JP 2020564814 A JP2020564814 A JP 2020564814A JP 2021513562 A5 JP2021513562 A5 JP 2021513562A5
- Authority
- JP
- Japan
- Prior art keywords
- coor
- halogen
- alkyl
- substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629956P | 2018-02-13 | 2018-02-13 | |
| US62/629,956 | 2018-02-13 | ||
| US16/272,172 US10519187B2 (en) | 2018-02-13 | 2019-02-11 | Cyclic dinucleotides as anticancer agents |
| US16/272,172 | 2019-02-11 | ||
| PCT/US2019/017740 WO2019160884A1 (en) | 2018-02-13 | 2019-02-13 | Cyclic dinucleotides as anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513562A JP2021513562A (ja) | 2021-05-27 |
| JP2021513562A5 true JP2021513562A5 (enExample) | 2022-05-26 |
| JP7296405B2 JP7296405B2 (ja) | 2023-06-22 |
Family
ID=67542132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564814A Active JP7296405B2 (ja) | 2018-02-13 | 2019-02-13 | 抗がん剤としての環状ジヌクレオチド |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10519187B2 (enExample) |
| EP (1) | EP3752516B1 (enExample) |
| JP (1) | JP7296405B2 (enExample) |
| KR (1) | KR102950614B1 (enExample) |
| CN (1) | CN111902420B (enExample) |
| AR (1) | AR114369A1 (enExample) |
| CY (1) | CY1125159T1 (enExample) |
| DK (1) | DK3752516T3 (enExample) |
| ES (1) | ES2909616T3 (enExample) |
| HR (1) | HRP20220520T1 (enExample) |
| HU (1) | HUE058662T2 (enExample) |
| LT (1) | LT3752516T (enExample) |
| PL (1) | PL3752516T3 (enExample) |
| PT (1) | PT3752516T (enExample) |
| RS (1) | RS63128B1 (enExample) |
| SI (1) | SI3752516T1 (enExample) |
| SM (1) | SMT202200168T1 (enExample) |
| TW (1) | TW202003539A (enExample) |
| WO (1) | WO2019160884A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| MX2022008123A (es) | 2020-01-16 | 2022-07-21 | Bristol Myers Squibb Co | Reactivos y su uso para modular la sintesis enantiodivergente de enlaces c-p. |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CR20160564A (es) * | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| CN110234403A (zh) * | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| JP7186764B2 (ja) * | 2017-07-28 | 2022-12-09 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| JP7208225B2 (ja) * | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| KR102812783B1 (ko) | 2017-08-31 | 2025-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
-
2019
- 2019-02-11 US US16/272,172 patent/US10519187B2/en active Active
- 2019-02-13 PT PT197075955T patent/PT3752516T/pt unknown
- 2019-02-13 ES ES19707595T patent/ES2909616T3/es active Active
- 2019-02-13 RS RS20220372A patent/RS63128B1/sr unknown
- 2019-02-13 JP JP2020564814A patent/JP7296405B2/ja active Active
- 2019-02-13 EP EP19707595.5A patent/EP3752516B1/en active Active
- 2019-02-13 DK DK19707595.5T patent/DK3752516T3/da active
- 2019-02-13 CN CN201980012869.9A patent/CN111902420B/zh active Active
- 2019-02-13 LT LTEPPCT/US2019/017740T patent/LT3752516T/lt unknown
- 2019-02-13 SI SI201930199T patent/SI3752516T1/sl unknown
- 2019-02-13 WO PCT/US2019/017740 patent/WO2019160884A1/en not_active Ceased
- 2019-02-13 KR KR1020207026044A patent/KR102950614B1/ko active Active
- 2019-02-13 TW TW108104810A patent/TW202003539A/zh unknown
- 2019-02-13 PL PL19707595T patent/PL3752516T3/pl unknown
- 2019-02-13 AR ARP190100352A patent/AR114369A1/es not_active Application Discontinuation
- 2019-02-13 HU HUE19707595A patent/HUE058662T2/hu unknown
- 2019-02-13 HR HRP20220520TT patent/HRP20220520T1/hr unknown
- 2019-02-13 SM SM20220168T patent/SMT202200168T1/it unknown
- 2019-11-14 US US16/683,667 patent/US11339185B2/en active Active
-
2022
- 2022-05-05 CY CY20221100320T patent/CY1125159T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513562A5 (enExample) | ||
| JP2020529400A5 (enExample) | ||
| JP2020536897A5 (enExample) | ||
| HRP20220520T1 (hr) | Ciklički dinukleotidi kao agensi protiv raka | |
| JP2020536971A5 (enExample) | ||
| JP2020532542A5 (enExample) | ||
| US11878000B2 (en) | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors | |
| CN110087680B (zh) | 使用包含btk抑制剂的组合产品治疗癌症 | |
| CN101678029B (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| JP6648040B2 (ja) | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 | |
| CN105999263B (zh) | 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法 | |
| JP2021073254A (ja) | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ | |
| CN107849050B (zh) | 化合物 | |
| JP2019501204A5 (enExample) | ||
| JP2020532529A5 (enExample) | ||
| CN119454706A (zh) | 治疗kras相关癌症的方法 | |
| JP2020531447A5 (enExample) | ||
| JP2020532539A5 (enExample) | ||
| AU2019244793B2 (en) | Anticancer pharmaceutical compositions for combined therapy | |
| TW202417055A (zh) | 抗ｓｅｚ６抗體藥物接合物 | |
| AU2008280105A1 (en) | Use of imidazoquinolines for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
| AU2012306122A1 (en) | Scheme for administering N-hydroxy-4-{2-[3-(N.N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
| JP2018524361A5 (enExample) | ||
| JP2021515016A5 (enExample) | ||
| CN119300868B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 |